ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of 2025 before the market opens on Tuesday, November 11, 2025, and host a conference call and webcast on the same date. Third Quarter 2025 Conference Call DetailsDate / Time: Tuesday, November 11, 2025 – 7:30 a.m. CDT, 8:30 a.m. EDT Speakers: Kevin Curet ...

Leadership Changes - Solésence, Inc. has announced the promotion of Kevin Cureton to President and Chief Executive Officer, with Laura Riffner appointed as Chief Financial Officer, and Jess Jankowski transitioning to Board Advisor [1][2] - These leadership changes are part of a broader strategic transformation aimed at enhancing the company's operational efficiency and market presence [2] Company Rebranding and Growth - In the first half of 2025, Solésence rebranded from Nanophase Technologies, reflecting the success of its Beauty Science platform and reinforcing its mission to deliver joy through innovation and inclusivity [2] - The company uplisted to Nasdaq on April 8, 2025, which has increased visibility with the investment community and is expected to drive greater shareholder value [2] Strategic Vision and Future Plans - The leadership transition is seen as a pivotal moment for Solésence, with a focus on delivering high-performance skin care, sun care, and color cosmetics products to consumers worldwide [2][3] - Kevin Cureton's leadership is expected to foster continued growth and innovation, while Laura Riffner's extensive financial experience will enhance operational excellence [3] Executive Experience - Laura Riffner brings over 35 years of experience in finance management and strategic planning, having previously served as CFO at Nagase America and Paxton/Patterson, where she improved operational efficiencies and financial forecasting [3][4]

Core Insights - Solésence, Inc. reported a strong financial performance for Q2 2025, with a revenue increase of 56% year-over-year, reaching a record $20.4 million compared to $13.0 million in Q2 2024 [10] - The company emphasized its commitment to innovation and effective commercial execution, which has attracted leading brands to partner with them [2][5] - Solésence expanded its debt facilities to enhance financial flexibility, increasing borrowing capacity from $14.2 million to $23.0 million, and extending loan maturity dates [10] Financial Results - Revenue for Q2 2025 was $20.4 million, a 56% increase from $13.0 million in Q2 2024 [10] - Gross profit for the quarter was $5.9 million, up from $3.7 million in the same period last year [10] - Net income for Q2 2025 was $2.7 million, compared to $0.9 million in Q2 2024, which included an Employee Retention Credit net receipt of approximately $1.2 million [10] Operational Highlights - Shipment volume increased by 102% year-over-year, while production volume rose by 127% year-over-year [10] - The company improved its gross margin sequentially from the first quarter, maintaining a gross margin of 29% [10][5] - Solésence achieved record unit volume during its peak demand season, reflecting effective operational management [5] Strategic Initiatives - The company amended its loan agreements to support long-term growth initiatives, enhancing its financial flexibility [10] - Solésence's focus on innovation is central to its value proposition, aiming to equip partners with differentiated consumer products [2]

Core Insights - Solésence, Inc. will report its second quarter 2025 results on July 31, 2025, after market close [1] - The company will host a conference call and webcast on the same date to discuss the results [1] Conference Call Details - The conference call is scheduled for July 31, 2025, at 4:00 p.m. CDT, 5:00 p.m. EDT [2] - Speakers will include Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer [2] - Registration is required to receive the dial-in number and personalized PIN for the call [2][3] Company Overview - Solésence, Inc. is a leader in scientifically-driven health care solutions in beauty and life science categories [4] - The company focuses on innovation, inclusivity, and the science of beautiful skin, particularly in mineral-based sun protection [4] - Solésence integrates protection, prevention, and treatment technologies into daily use products, enhancing skin health solutions [4]

Core Insights - Solésence, Inc. has amended its loan agreements to increase borrowing capacity and extend maturity dates, enhancing financial flexibility for strategic objectives [1][2][3] Financial Details - The maximum borrowing capacity has increased from $14.2 million to $23.0 million, with maturity dates extended from October 1, 2025, to April 30, 2027 [2] Strategic Objectives - The additional borrowing capacity will support procurement of key raw materials, improve lead times for packaging and product launches, and empower brand partners to drive product adoption [3] Leadership Commentary - The President and CEO of Solésence emphasized that the increased financial capacity and extended timeline will be crucial for scaling operations and serving brand partners effectively [4]

Core Insights - Solésence, Inc. reported record revenue of $14.6 million for Q1 2025, a 48% increase from $9.9 million in Q1 2024, driven by strong sales and large customer orders [7][2] - The company experienced a significant increase in shipment volume by 95% year-over-year and production volume by 120% year-over-year, indicating robust operational growth [7][2] - Solésence has successfully uplisted to Nasdaq under the ticker "SLSN," enhancing its visibility in the investment community [6][2] Financial Performance - Revenue for Q1 2025 was $14.6 million, up from $9.9 million in Q1 2024, marking a 48% increase [7] - Gross profit decreased to $3.3 million in Q1 2025 from $3.6 million in Q1 2024, resulting in a gross margin of 23%, down from 36% in the previous year [7] - Net income for Q1 2025 was breakeven, compared to a net income of $0.9 million in Q1 2024 [7] Operational Highlights - The company launched a multi-SKU product line for a new strategic brand partner, which incurred one-time start-up costs affecting gross margins [2] - Solésence anticipates continued sequential revenue growth with current shipped and open orders exceeding $45 million [2] - The company has expanded its intellectual property portfolio with new technology allowances in Japan, South Korea, and Mexico [7] Future Outlook - Management expects substantial improvement in gross margin levels as operations scale and fixed manufacturing costs are managed more efficiently [2] - The company aims to capitalize on significant opportunities to drive long-term shareholder value following its Nasdaq uplisting and rebranding efforts [2]

Core Viewpoint - Solésence, Inc. will report its first quarter 2025 results on May 5, 2025, and will host a conference call and webcast on the same day [1]. Group 1: Conference Call Details - The conference call is scheduled for May 5, 2025, at 4:00 p.m. CDT (5:00 p.m. EDT) [2]. - Speakers for the call will include Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer [2]. - Participants must register to receive the dial-in number and personalized PIN [2]. Group 2: Company Overview - Solésence, Inc. is a leader in scientifically-driven health care solutions in beauty and life science categories [4]. - The company's mission focuses on delivering joy through innovation, inclusivity, and the science of beautiful skin [4]. - Solésence has redefined mineral-based sun protection by enhancing transparency, effectiveness, aesthetics, and wearability [4].